Skip to main content

Fibrillary Glomerulonephritis

Fibrillary Glomerulonephritis




Overview

Fibrillary GN is a disease which affects the millions of filtering units that make up the kidney. These filtering units are called glomeruli. Each individual glomerulus is composed of multiple layers of straining material.


In this condition, the body produces a large volume of unusual proteins. These proteins enter the filters. The proteins become trapped in the straining layers, disrupting filtration. In some instances these proteins activate the immune system. This causes swelling in these delicate structures.


Over time the swelling can damage the layers of the filters. The damage allows large amounts of proteins to spill into the urine. As the swelling progresses filtering units are damaged beyond repair. They are replaced by scar tissue.


With the loss of enough filters, the kidneys lose the ability to filter and clean the blood. This condition is known as end-stage kidney disease.


This disease has been found in patients age 10 to 89. It appears to affect Caucasians at a slightly higher rate. We cannot predict who will develop it. It appears there may be an association of this disease with conditions of immune system dysfunction, such as lupus. This disease can also be found in association with diseases causing chronic immune system activation, such as Hepatitis C.


SYNONYMS

fibrillary GN

non-amyloid fibrillary glomerulopathy

Congo red-negative amyloidosis-like glomerulopathy

don-amyloid fibrillary glomerulonephritis

SIGNS & SYMPTOMS

The most common symptoms of fibrillary glomerulonephritis include:


Blood in the urine (hematuria)

Protein in the urine (proteinuria) causing it to look “foamy”

Decreased kidney function (renal insufficiency)

High blood pressure (hypertension)


CAUSES

The causes of fibrillary glomerulonephritis are currently unknown and are being researched. Antibodies (immunoglobulins) build up in the glomerulus, often in patients with an underlying disease such as cancer (particularly leukemia, lymphoma and multiple myeloma), a monoclonal gammopathy or an autoimmune disease (Crohn’s disease, Graves’ disease, immune thrombocytopenia, etc.).


AFFECTED POPULATIONS

Patients with a history of cancer (particularly leukemia or multiple myeloma), a monoclonal gammopathy or an autoimmune disease (particularly Crohn’s disease, lupus, Graves’ disease, or immune thrombocytopenia [ITP]) are at risk for fibrillary glomerulonephritis.


DISORDERS WITH SIMILAR SYMPTOMS

Immunotactoid glomerulopathy – a similar disease in which antibodies (immunoglobulins) and microtubules affect the glomerulus rather than fibrils.


Fibronectin glomerulopathy – a similar disease in which a protein called fibronectin-1 affects the glomerulus rather than fibrils.


Collagenofibrotic glomerulopathy – a similar disease in which collagen affects the glomerulus rather than fibrils.


DIAGNOSIS

A diagnosis is made from a kidney biopsy to look at the fibrils under an electron microscope and immunofluorescence microscope. Routine lab tests may detect the blood and protein in the urine, but a biopsy is the only way to determine which proteins are affecting the glomerulus.


Clinical Testing and Work-up


Abnormal results from routine blood and urine tests are the first line of evidence for kidney damage. Kidney function tests can then detect the severity of kidney damage. After a kidney biopsy confirms the diagnosis of fibrillary glomerulonephritis, a physician will likely order more blood tests and imaging. These tests are important to find any underlying cancer, hepatitis or autoimmune disease which may be associated with the glomerulonephritis. In some patients, finding and treating the underlying condition can decrease the severity of the kidney disease. In the case when an underlying condition is not found, treatment focuses on controlling the hypertension, protein in the urine and progression of the kidney disease.


STANDARD THERAPIES

Treatment


There is currently no approved therapy to treat fibrillary glomerulonephritis with unknown cause. Many therapies have been tried with little success including steroids, plasmapheresis, cyclophosphamide and cyclosporine. Clinicians will likely focus instead on controlling the symptoms such as hypertension, proteinuria and kidney insufficiency. If an underlying condition is present (see Affected Populations), clinicians will instead focus on treating the underlying condition, which may improve symptoms of fibrillary glomerulonephritis.


Patients who progress to end-stage renal disease will likely need a kidney transplant and/or dialysis, although fibrillary glomerulonephritis can recur after a kidney transplant.

TYPE OF DOCTOR AND DEPARTMENT: Kidney Specialist  and  Nephrologist Specialist can diagnose these disease.

 

Comments

Post a Comment

Popular posts from this blog

Charge Syndrome

Overview CHARGE syndrome is a recognizable genetic syndrome with known pattern of features. It is an extremely complex syndrome, involving extensive medical and physical difficulties that differ from child to child. CHARGE syndrome is correlated with genetic mutation to CHD7 and the prevalence of CHARGE syndrome is 1:10,000-1:15,000 live births. Babies with CHARGE syndrome are often born with life-threatening birth defects. They spend many months in the hospital and undergo many surgeries and other treatments. Swallowing and breathing problems make life difficult even when they come home. Most have hearing two little girls sitting on a carpet, one girl has a trach and is biting her finger.loss, vision loss, and balance problems that delay their development and communication. Despite these seemingly insurmountable obstacles, children with CHARGE syndrome often far surpass their medical, physical, educational, and social expectations. One of the hidden features of CHARGE syndrome is the ...
7 comments
Read more

HMSN Type I

 HMSN Type I Overview Hereditary motor and sensory neuropathy type 1 (HMSN I), also known as Charcot-Marie-Tooth disease type 1 (CMT1), is a group of inherited neurological disorders affecting the peripheral nerves. It is characterized by progressive muscle weakness and wasting, primarily in the feet and legs, as well as sensory loss. HMSN I is the most common form of HMSN and is typically caused by a duplication on chromosome 17p11.2-p12, including the PMP22 gene.  Symptoms Numbness and tingling: Often starting in the feet and potentially extending to the hands, these sensations can mimic poor circulation.  Reduced ability to feel pain and temperature: This can lead to unnoticed injuries and complications.  Motor Symptoms: Muscle weakness and wasting: Primarily affecting the distal muscles (those farthest from the body's core), such as the feet and hands.  Foot deformities: High arches (pes cavus) and hammer toes are frequently observed.  Gait abnormalit...
Post a Comment
Read more

Sjogren's syndrome

Sjogren's syndrome Overview Sjogren's (SHOW-grins) syndrome is a disorder of your immune system identified by its two most common symptoms — dry eyes and a dry mouth. The condition often accompanies other immune system disorders, such as rheumatoid arthritis and lupus. In Sjogren's syndrome, the mucous membranes and moisture-secreting glands of your eyes and mouth are usually affected first — resulting in decreased tears and saliva. Although you can develop Sjogren's syndrome at any age, most people are older than 40 at the time of diagnosis. The condition is much more common in women. Treatment focuses on relieving symptoms. Symptoms The two main symptoms of Sjogren's syndrome are: Dry eyes . Your eyes might burn, itch or feel gritty — as if there's sand in them. Dry mouth. Your mouth might feel like it's full of cotton, making it difficult to swallow or speak. Some people with Sjogren's syndrome also have one or more of the following: Joint pain, swel...
Post a Comment
Read more